Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin.
Yamasaki. Kenshi K; Schauber. Jürgen J; Coda. Alvin A; Lin. Henry H; Dorschner. Robert A RA; Schechter. Norman M NM; Bonnart. Chrystelle C; Descargues. Pascal P; Hovnanian. Alain A; Gallo. Richard L RL
Key Findings
- Kallikrein 5 (SCTE) and kallikrein 7 (SCCE) process hCAP18 into LL‑37 and other peptides in skin.
- Mice lacking the protease inhibitor LEKTI have higher skin antimicrobial activity due to unchecked kallikrein activity.
- Inhibiting or enhancing these proteases changes the amount and type of antimicrobial peptides produced.
Practical Outcomes
- For DIY health enthusiasts, the work suggests that topical agents that modulate kallikrein activity—either by inhibiting excess proteases or by supporting their proper function—could influence skin immunity. However, no specific dosage or product is provided, so any experimentation should be cautious and based on further safety data.
Summary
The study shows that skin enzymes called kallikreins cut the precursor of the antimicrobial peptide LL‑37 into its active form and other smaller pieces, and that the balance of these enzymes controls how well the skin can fight microbes.
Abstract
The presence of cathelicidin antimicrobial peptides provides an important mechanism for prevention of infection against a wide variety of microbial pathogens. The activity of cathelicidin is controlled by enzymatic processing of the proform (hCAP18 in humans) to a mature peptide (LL-37 in human neutrophils). In this study, elements important to the processing of cathelicidin in the skin were examined. Unique cathelicidin peptides distinct from LL-37 were identified in normal skin. Through the use of selective inhibitors, SELDI-TOF-MS, Western blot, and siRNA, the serine proteases stratum corneum tryptic enzyme (SCTE, kallikrein 5) and stratum corneum chymotryptic protease (SCCE, kallikrein 7) were shown to control activation of the human cathelicidin precursor protein hCAP18 and also influence further processing to smaller peptides with alternate biological activity. The importance of this serine protease activity to antimicrobial activity in vivo was illustrated in SPINK5-deficient mice that lack the serine protease inhibitor LEKTI. Epidermal extracts of these animals show a significant increase in antimicrobial activity compared with controls, and immunoabsorption of cathelicidin diminished antimicrobial activity. These observations demonstrate that the balance of proteolytic activity at an epithelial interface will control innate immune defense.
Study Information
pubmed
2006
10.1096/fj.06-6075com